Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study [Yahoo! Finance]
Moleculin Biotech, Inc. (MBRX)
Last moleculin biotech, inc. earnings: 8/16 05:35 pm
Check Earnings Report
US:NASDAQ Investor Relations:
moleculin.com/investors
Company Research
Source: Yahoo! Finance
HOUSTON, March 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next segment on its CEO Corner, a platform featuring Walter Klemp, Chief Executive Officer. The CEO Corner is designed to provide investors and stakeholders with enhanced insight into the Company's corporate developments, clinical progress and strategic initiatives. As part of the segment, Mr. Klemp discussed progress on the Company's pivotal MIRACLE Study evaluating Annamycin in combination with cytarabine (AnnAraC) for patients with relapsed or refractory Acute Myeloid Leukemia. Mr. Klemp explained that the adaptive Phase 3 trial was designed with input from the U.S. Food and Drug Administration and includes an initial cohort of 45 patients. After treatment of these patients is completed, the study will undergo an interim unblinding to evaluate safety and efficacy and help inform the most efficient regulatory path forward. Enroll
Show less
Read more
Impact Snapshot
Event Time:
MBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBRX alerts
High impacting Moleculin Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
MBRX
News
- Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE StudyGlobeNewswire
- Moleculin Announces Exercise of Warrants for $8.3 Million Gross ProceedsGlobeNewswire
- Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)GlobeNewswire
- Moleculin Announces Notice of Allowance for Japanese Patent Covering AnnamycinGlobeNewswire
- Moleculin Launches CEO Corner Platform to Share Strategic InsightsGlobeNewswire
MBRX
Sec Filings
- 3/9/26 - Form DEF
- 2/27/26 - Form PRE
- 2/20/26 - Form 8-K
- MBRX's page on the SEC website